Publications by authors named "R Koschny"
Background And Aims: Boerhaave syndrome, an effort rupture of the esophagus, is a rare but serious condition. Endoscopic vacuum therapy (EVT) is a new therapeutic approach for GI perforation. We aimed to evaluate EVT for treatment of Boerhaave syndrome.
View Article and Find Full Text PDFBackground And Aims: This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx).
Methods: Endoscopic biopsies of patients with locally advanced EGC (n = 120) were taken into culture and PDOs expanded. PDOs' response towards the single substances of the FLOT regimen and the combination treatment were correlated to patients' pathological response using tumor regression grading.
Background/aim: Systemic treatment for metastatic colorectal cancer (CRC) includes chemotherapy in combination with a targeted antibody. Novel targeted therapies and immunotherapies are introduced for specific molecular subgroups. Prognostic relevant determinants are still under investigation.
View Article and Find Full Text PDFPurpose: Brain metastasis formation is a rare and late event in colorectal cancer (CRC) patients and associated with poor survival. In contrast to other metastatic sites, the knowledge on chromosomal aberrations in brain metastases is very limited.
Methods: Therefore, we carried out single nucleotide polymorphism (SNP) array analyses on matched primary CRC and brain metastases of four patients as well as on liver metastases of three patients.
Article Synopsis
- - Antibiotics can reduce the effectiveness of PD-1 blockade in cancer treatment, but we still don’t fully understand how they weaken immune responses.
- - The study found that after antibiotics, certain gut bacteria lead to a decrease in MAdCAM-1, promoting regulatory T cells to leave the gut and move into tumors, which negatively impacts immune function.
- - In cancer patients, lower levels of soluble MAdCAM-1 in the blood were associated with poorer outcomes, suggesting that targeting the MAdCAM-1-α4β7 pathway could improve cancer immunotherapy strategies.